Cook Jennifer E. 4

What Happened

• Jennifer E. Cook, a director of BridgeBio Pharma (BBIO), exercised two stock option tranches on June 24, 2026 (20,000 shares at $8.45 and 17,167 shares at $16.75), paying $456,547 in exercise price. She sold 37,167 of the shares acquired from those exercises the same day at $70.00 for $2,601,690. Separately, on June 23, 2026 she sold 2,196 shares in the open market at $68.57 for $150,580. On June 22, 2026 she was also granted 3,990 and 5,277 restricted stock units (RSUs) (total 9,267 RSUs) that vest on June 22, 2027.

Key Details

• Transaction dates and prices:
  • 2026-06-24: Exercised 20,000 shares @ $8.45 (cost $169,000) and 17,167 shares @ $16.75 (cost $287,547); sold 37,167 shares @ $70.00 (proceeds $2,601,690).
  • 2026-06-23: Sold 2,196 shares @ $68.57 (proceeds $150,580) under a Rule 10b5-1 plan.
  • 2026-06-22: Granted 3,990 RSUs and 5,277 RSUs (total 9,267 RSUs) — RSUs vest 6/22/2027.
• Total sales proceeds reported: about $2,752,270; total exercise cost reported: $456,547.
• The filing includes derivative "disposed" line items at $0.00 for 37,167 shares on 6/24 (these relate to the option exercises/settlement reported on the same form).
• The 6/23 sale was effected pursuant to a Rule 10b5-1 trading plan adopted March 16, 2026 (per footnote).
• Shares owned after the transactions are not specified in the Form 4 excerpt provided.
• Filing date: Form filed 2026-06-24 covering transactions 2026-06-22 to 2026-06-24; filing appears timely.

Context

• Exercising options and selling the resulting shares the same day is commonly a cashless exercise/sale pattern (here exercises and sales occurred on 6/24). That typically converts option holdings into cash but does not by itself indicate the director's longer-term view.
• RSU grants vest in the future (6/22/2027) and are contingent on continued board service per the footnotes.
• The 10b5-1 plan used for the 6/23 sale indicates the sale was pre-planned, which is routine for insiders and intended to avoid timing concerns.